WEBULL
WebtradeDownload

Waystar Holding (WAY) Could Be 26% Undervalued As AltitudeAI Expansion Takes Shape

Simply Wall St · 1d ago

Waystar Holding (WAY) is back in focus after unveiling new AltitudeAI capabilities that automate claim resubmission, clinical documentation support, analytics, and patient financial engagement, alongside fresh leadership appointments in product and commercial roles.

Despite the fresh AltitudeAI updates and leadership hires, Waystar Holding’s share price has come under pressure in the short term, with a 1-day share price return of 3.87% and a 7-day share price return of 4.46% at a latest share price of US$25.07. This compares with a 90-day share price return of 25.35%, a year-to-date share price return decline of 20.08%, and a 1-year total shareholder return decline of 32.73%, suggesting recent momentum has picked up after a weaker stretch for longer term holders.

Compare Waystar Holding's push into healthcare AI with a hand picked group of US-listed peers by scanning the 37 healthcare AI stocks now shaping automation and analytics in the sector.

Waystar Holding is pushing hard on healthcare AI and posting double digit growth in both revenue and net income. The real issue now is whether a US$5.0b stock at US$25.07 still offers enough value.

Most Popular Narrative: 25.9% Undervalued

Waystar Holding's most followed narrative places fair value at $33.83 a share, comfortably above the recent $25.07 price, which is why the valuation debate is so active.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar's total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth.

Read the complete narrative. Read the complete narrative.

Investors may want to understand how this AI-focused strategy and acquisition plan are reflected in the higher fair value estimate. The narrative emphasizes steady revenue expansion, improving margins and a richer earnings multiple to support that valuation.

Result: Fair Value of $33.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Waystar Holding’s story can change quickly if leverage from the US$1.25b Iodine deal constrains flexibility or if larger provider clients push harder on pricing.

Find out about the key risks to this Waystar Holding narrative.

Another View on Waystar Holding’s Valuation

While the popular narrative frames Waystar Holding as about 25.9% undervalued at a fair value of $33.83, the current P/E of 35.7x tells a more mixed story. It is lower than peer averages at 51.6x, higher than the global Healthcare Services group at 28.6x, and above the SWS fair ratio of 33x.

This gap suggests some valuation risk if the market moves closer to the fair ratio or the broader industry. At the same time, it also shows investors are not paying as much as for certain peers. The key question is whether Waystar Holding’s AI push and profit growth justify staying above that fair ratio for long.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:WAY P/E Ratio as at Sep 2026
NasdaqGS:WAY P/E Ratio as at Sep 2026

Next Steps

The mixed messages on Waystar Holding’s valuation and AI potential make this a stock where your own judgment really matters. Consider acting while sentiment is still forming and scrutinize the upside factors by reviewing the 4 key rewards.

Looking for more investment ideas beyond Waystar Holding?

If Waystar Holding is on your radar, do not stop there. Broaden your watchlist with other clear ideas so you are not leaving potential opportunities on the table.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.